Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TheraPlaza

(Nimotuzumab)

Phase 3Monoclonal antibody

BBiotech Pharmaceutical Co., Ltd.

Nimotuzumab is used to treat certain types of cancer, particularly head and neck cancer and pancreatic cancer, by blocking a protein that helps cancer cells grow.[1] TheraPlaza is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]

TheraPlaza is one of 382 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

17

Indications

108

Total Trials

33

Active Trials

381

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaWithdrawn

Nasopharyngeal CarcinomaUnknown status

Esophageal CancerCompleted

Head and Neck Malignant NeoplasiaUnknown

Cervical CarcinomaCompleted

Liver CancerRecruiting

Pancreatic Ductal AdenocarcinomaRecruiting

Neuroendocrine NeoplasmNot yet recruiting

Pancreatic CancerNot yet recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Withdrawn

Nasopharyngeal CarcinomaPhase 3

Unknown status

Esophageal CancerPhase 3

Completed

Head and Neck Malignant NeoplasiaPreclinical

Unknown

Cervical CarcinomaPhase 3

Completed

Liver CancerPhase 2

Recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Recruiting

Neuroendocrine NeoplasmPhase 2

Not yet recruiting

Pancreatic CancerPhase 3

Not yet recruiting

Head and Neck Squamous Cell CarcinomaPhase 3

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

TheraPlaza

BBiotech Pharmaceutical Co., Ltd.

Medrol

Byetta

MS Contin

HHikma Pharmaceuticals LLC

Xylocaine

MMEDRx USA, Inc.

Feraheme

AAzurity Pharmaceuticals

Active Comparator

Secretin-Ferring

Sulfonylureas

HB-Admscs

HHope Biosciences Research Foundation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Cervical Squamous Cell Carcinoma

NCT04976478

Phase 2Not yet recruiting

Neuroendocrine Neoplasm

NCT05316480

Q1 2027

Phase 1/2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06773130

Q2 2027

Phase 2Recruiting

Esophageal Squamous Cell Carcinoma

NCT06988956

Phase 2/3Not yet recruiting

Pancreatic Cancer

NCT06409429

Phase 2Recruiting

Nasopharyngeal Carcinoma

NCT06509009

Clinical

Trials by Indication[1]

Pancreatic Cancer13 trials

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Not yet recruiting·PPeking University Third Hospital·Phase 2·NCT06422156·73 enrolled

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07277452·156 enrolled

Nimotuzumab in Adults With Pancreatic Cancer

Completed·OOncoscience AG·Phase 2/3·NCT00561990·188 enrolled

Show 10 more trials

A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Completed·RRuijin Hospital··NCT06363084·64 enrolled

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06404840·30 enrolled

Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06405685·30 enrolled

AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06938503·48 enrolled

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT06409429·146 enrolled

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

Recruiting·ZZhejiang Provincial People's Hospital·Phase 2·NCT06722911·57 enrolled

Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06389760·57 enrolled

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Completed·BBiotech Pharmaceutical Co., Ltd.·Phase 3·NCT02395016·90 enrolled

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Recruiting·ZZhejiang University·Phase 2·NCT06770452·32 enrolled

A Phase Ib/II Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

Not yet recruiting·ZZhejiang University·Preclinical·NCT07736612·80 enrolled

Nasopharyngeal Carcinoma10 trials

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03666221·67 enrolled

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recruiting·MMing-Yuan Chen·Phase 2·NCT07070479·208 enrolled

Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03915132·47 enrolled

Show 7 more trials

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06912711·70 enrolled

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT03837808·384 enrolled

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

Unknown status·BBiotech Pharmaceutical Co., Ltd.·Phase 4·NCT02293356·2,000 enrolled

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Completed·ZZhejiang Cancer Hospital·Phase 2·NCT03025958·30 enrolled

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Recruiting·FFourth Affiliated Hospital of Guangxi Medical University·N/A·NCT05717790·288 enrolled

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Recruiting·FFudan University·Phase 3·NCT05772208·459 enrolled

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting·—·Phase 2·NCT06509009·30 enrolled

Esophageal Cancer8 trials

Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06048913·56 enrolled

A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer

Completed·EEurofarma Laboratorios S.A.·Phase 2/3·NCT01249352·104 enrolled

Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT01463605·46 enrolled

Show 5 more trials

Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer

Completed·BBiotech Pharmaceutical Co., Ltd.·Phase 1·NCT00950417·11 enrolled

A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Completed·—·Phase 2·NCT04207918·55 enrolled

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Completed·BBiotech Pharmaceutical Co., Ltd.·Phase 2·NCT02591784·42 enrolled

Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy

Unknown status·FFudan University·Phase 2/3·NCT01402180·128 enrolled

Neoadjuvant Treatment Modalities in Esophageal Cancer

Recruiting·—·Phase 3·NCT04821843·2,000 enrolled

Esophageal Squamous Cell Carcinoma8 trials

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06718205·112 enrolled

A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Unknown status·SShandong Cancer Hospital and Institute·Phase 3·NCT02409186·200 enrolled

Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.

Unknown status·PPeking University·Phase 1/2·NCT01993784·9 enrolled

Show 5 more trials

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

Enrolling by invitation·PPeking University·Phase 2·NCT07312578·48 enrolled

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Withdrawn·PPeking University·Phase 2/3·NCT02272699

Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma

Unknown status·BBiotech Pharmaceutical Co., Ltd.·Phase 2·NCT01232374·144 enrolled

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06988956·95 enrolled

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Unknown status·BBiotech Pharmaceutical Co., Ltd.·Phase 3·NCT02611700·504 enrolled

Cervical Cancer4 trials

Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Unknown status·—·Phase 2·NCT02705612·60 enrolled

A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer

Completed·NNational Institute of Cancerología·Phase 1/2·NCT02095119·15 enrolled

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer

Unknown status·BBiotech Pharmaceutical Co., Ltd.·Phase 2·NCT02039791·20 enrolled

Show 1 more trial

Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Unknown status·ZZhujiang Hospital·Phase 2·NCT03469531·100 enrolled

46 more indications

Head and Neck Squamous Cell Carcinoma4 trials

A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Active, not recruiting·BBiotech Pharmaceutical Co., Ltd.·Phase 4·NCT06879691·171 enrolled

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 3·NCT07445048·370 enrolled

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Completed·FFudan University·Phase 2·NCT00910117·40 enrolled

Show 1 more trial

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting·SShandong Cancer Hospital and Institute·Phase 3·NCT07333274·335 enrolled

Radiation Therapy3 trials

Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab

Withdrawn·EEurofarma Laboratorios S.A.·Phase 3·NCT01345084

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Withdrawn·EEurofarma Laboratorios S.A.·Phase 2·NCT01301612

A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

Terminated·YYM BioSciences·Phase 2·NCT00872482·21 enrolled

Non-Small Cell Lung Cancer3 trials

A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Terminated·YYM BioSciences·Phase 1/2·NCT00369447·52 enrolled

Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer

Unknown status·BBiotech Pharmaceutical Co., Ltd.·N/A·NCT02549261·150 enrolled

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT02947386·7 enrolled

Esophageal Carcinoma3 trials

Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma

Withdrawn·ZZhejiang University·Phase 2·NCT02034968

Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02858206·120 enrolled

Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma

Withdrawn·ZZhejiang University·Phase 2·NCT02011594

Lung Cancer2 trials

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Unknown status·HHui Bu·Phase 2·NCT04833205·30 enrolled

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02577341·122 enrolled

Head Neck Cancer2 trials

Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Unknown status·NNational Cancer Centre, Singapore·Phase 3·NCT00957086·710 enrolled

A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined With Radiotherapy for Elderly Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Not yet recruiting·KKe Hu·Phase 2·NCT07821242·46 enrolled

Chemotherapy2 trials

Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT02672241·30 enrolled

Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT04882462·100 enrolled

Cervical Carcinoma2 trials

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Not yet recruiting·BBiotech Pharmaceutical Co., Ltd.·Phase 3·NCT06333821·460 enrolled

Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma

Completed·BBiotech Pharmaceutical Co., Ltd.·Phase 3·NCT06781073·118 enrolled

Efficacy and Safety2 trials

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN

Completed·BBiotech Pharmaceutical Co., Ltd.··NCT04949503·1,931 enrolled

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07457528·46 enrolled

Cervical Squamous Cell Carcinoma2 trials

Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma

Unknown status·PPeking University Third Hospital·N/A·NCT04678791·286 enrolled

Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

Not yet recruiting·PPeking University Third Hospital··NCT04976478·125 enrolled

Squamous Cell Carcinoma2 trials

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Active, not recruiting·—·Phase 2·NCT06771596·43 enrolled

Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus

Withdrawn·ZZhejiang University·Phase 2·NCT02041819

Glioma2 trials

Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma

Completed·EEurofarma Laboratorios S.A.·Phase 2·NCT01145170·40 enrolled

Nimotuzumab in Children With Intrinsic Pontine Glioma

Completed·OOncoscience AG··NCT00561691·41 enrolled

Gastric Adenocarcinoma2 trials

Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma

Unknown status·PPeking University·Phase 2·NCT03400592·55 enrolled

Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT02370849·2 enrolled

Glioblastoma2 trials

Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

Completed·BBiotech Pharmaceutical Co., Ltd.·Phase 2·NCT03388372·39 enrolled

Nimotuzumab in Adults With Glioblastoma Multiforma

Completed·OOncoscience AG·Phase 3·NCT00753246·150 enrolled

Anal Canal Cancer1 trial

Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers

Terminated·—·Phase 2·NCT01382745·1 enrolled

Phase II1 trial

Phase II Umbrella Study Directed by Next Generation Sequencing

Unknown status·GGuangdong Association of Clinical Trials·Phase 2·NCT03574402·400 enrolled

Radiotherapy1 trial

Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Unknown status·EEye & ENT Hospital of Fudan University·Phase 2·NCT05024019·95 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·WWest China Hospital·Phase 1/2·NCT06773130·20 enrolled

Chemoradiotherapy1 trial

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Recruiting·—·Phase 3·NCT04821778·2,000 enrolled

Penile Cancer1 trial

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Completed·SSun Yat-sen University·Phase 2·NCT04475016·29 enrolled

Gastroesophageal Junction Cancer1 trial

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Terminated·KKuhnil Pharmaceutical Co., Ltd.·Phase 3·NCT01813253·400 enrolled

Squamous Cell Lung Carcinoma1 trial

Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

Withdrawn·SSun Yat-sen University·Phase 2·NCT02428764

Advanced Cancer1 trial

Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Unknown status·HHangzhou Cancer Hospital·Phase 1·NCT03554889·21 enrolled

Head and Neck Squamous Cell Cancer1 trial

Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer

Completed·NNational Cancer Centre, Singapore·Phase 2·NCT00702481·32 enrolled

Esophageal Squamous Cell Cancer1 trial

Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer

Unknown status·PPeking University·Phase 2·NCT01336049·70 enrolled

Breast Cancer1 trial

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01939054·90 enrolled

Gastric Cancer1 trial

Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01180166·30 enrolled

Pharynx Cancer1 trial

Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer

Unknown status·TThe Second People's Hospital of Sichuan·Phase 2·NCT01516996·80 enrolled

Nasopharyngeal Cancer1 trial

Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

Unknown status·BBiotech Pharmaceutical Co., Ltd.·Phase 3·NCT01074021·480 enrolled

Colorectal Cancer1 trial

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Completed·BBiotech Pharmaceutical Co., Ltd.·Phase 1/2·NCT05278728·31 enrolled

Vinorelbine1 trial

Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom

Completed·EEl Kendi Pharmaceuticals Manufacturing Company·Phase 3·NCT03413579·37 enrolled

Solid Tumours1 trial

Phase I Study of Nimotuzumab in Solid Tumours

Completed·YYM BioSciences·Phase 1·NCT00369252·18 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

Completed·YYM BioSciences·Phase 2·NCT00600054·44 enrolled

Locally Advanced1 trial

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Recruiting·TTang-Du Hospital·Phase 2·NCT07353723·10 enrolled

Oral Squamous Cell Carcinoma1 trial

A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

Unknown status·XXin-Hua Xu·Phase 2·NCT04367909·68 enrolled

Solid Tumors1 trial

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Unknown status·TTianjin Medical University Second Hospital·N/A·NCT06022276·46 enrolled

Patients With Locally Advanced Rectal Cancer1 trial

Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01899118·50 enrolled

Elective1 trial

Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03620032·54 enrolled

Induction Chemotherapy1 trial

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

Unknown status·GGuiyang Medical University·Phase 2·NCT03557112·180 enrolled

Liver Cancer1 trial

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06413017·30 enrolled

Metastatic Colorectal Cancer1 trial

Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer

Terminated·YYM BioSciences·Phase 2·NCT00493857·100 enrolled

Neuroendocrine Neoplasm1 trial

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Not yet recruiting·FFudan University·Phase 2·NCT05316480·42 enrolled

Solid Tumor1 trial

Pharmacokinetics Study of Nimotuzumab Single-dose and Multiple-dose in Combination With Irinotecan in Patients With Solid Tumors

Completed·BBiotech Pharmaceutical Co., Ltd.·Phase 1·NCT02395068·39 enrolled

Refractory Metastatic Colorectal Cancer1 trial

Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Trifluridine/Tipiracil in Third-line and Beyond for the Treatment of Metastatic Colorectal Cancer

Withdrawn·BBiotech Pharmaceutical Co., Ltd.·Phase 3·NCT06343116

Nasopharyngeal Carcinoma (NPC)1 trial

Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Multicenter, Randomized, Open-Label, Non-Inferiority Phase III Clinical Study

Recruiting·SSun Yat-sen University·Phase 3·NCT07706985·566 enrolled

Glioma, Malignant1 trial

A Single-arm, Phase II Study of Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma

Not yet recruiting·TTianjin First Central Hospital·Phase 2·NCT07707973·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 108 trial records for Nimotuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nimotuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nimotuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biotech Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Epidermal Growth Factor Receptor Erbb1 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: BBiotech Pharmaceutical Co., Ltd.

Related News